SOAT1 and neoplasm: In the study, patients were stratified into the following three biomarker-defined cohorts: Cohort 1—patients with activating JAK and/or STAT mutations; Cohort 2—patients with more than 30% pSTAT3 expression among tumor cells by immunohistochemistry; and Cohort 3—patients lacking adequate tissue for evaluation or with no tissue for assessment.